

## Anti-TROP2 Antibody (Sacituzumab)

### Introduction

Sacituzumab is a humanized IgG1 monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2). Sacituzumab alone lacks anti-tumor effects, does not inhibit the function of TROP-2 during tumor metastasis, and can bind to the linear epitope of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugate (ADC) drugs. The TROP-2-targeting sacituzumab (sacituzumab govitecan) (HY -132254) antibody-drug conjugate has been approved for use in the field of triple-negative breast cancer.

### Product parameters

Alternative Names	HRS7
Target Accession	P09758
Target	TROP2
CAS number	1796566-95-4
Molecular Weight	145.52 kDa
Host	CHO
Reactivity	Human, Mouse
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human TROP2 His at 2 ug/mL can bind Anti-TROP2 Antibody (Sacituzumab), EC50=0.004316 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years

## Note

1. This product is for scientific research use only.



### APEx BIO Technology

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

